Trius Hires Chief Commercial Officer
SAN DIEGO, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that J. Craig Thompson has been appointed to the newly created role of Chief Commercial Officer. With more than 18 years of pharmaceutical marketing and sales experience, Craig will initially be responsible for developing the commercial strategy, positioning and planning for the potential launch of torezolid phosphate, an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections.
Before joining Trius, Craig was Vice President of Marketing for Pfizer's Specialty Care Business Unit where he was directly responsible for the U.S. commercial strategy for products with over $1.5 billion in annual U.S. sales including the first generation oxazolidinone Zyvox ®, the anti-infectives Tygacil ®, Vfend ® and Eraxis ® as well as Rapammune ® and Relistor ®. Prior to his 7 years at Pfizer, Craig served in positions of increasing responsibility during his 12 years at Merck where he most notably worked on the commercial planning and marketing activities for the company's anti-infectives Primaxin ®, Mefoxin ® and Cancidas ® as well as on major cardiovascular brands including Vytorin ®, Zetia ® and Zocor ®.
"Craig is a key addition to our management team and we believe that his strong infectious disease background combined with his experience in launching industry blockbusters will provide Trius with valuable commercial leadership," stated Dr. Jeffrey Stein, President and CEO of Trius Therapeutics. "His success in infectious diseases is especially relevant to his newly created role at Trius. Craig launched and led Primaxin to a position of growth, led the recent re-launch of Zyvox and effectively managed the co-positioning of Zyvox and Tygacil following the Pfizer/Wyeth merger.""Trius provides a unique opportunity to launch torezolid phosphate, a best-in-class oxazolidinone, and to contribute to the development of its preclinical portfolio," stated Craig Thompson. "I look forward to joining this exciting company, leading the commercialization of torezolid phosphate into a successful anti-infective drug and creating value for our customers and shareholders."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV